Skip to main content

Table 2 PIPAC procedures

From: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for rare gynecologic indications: peritoneal metastases from breast and endometrial cancer

Characteristic / Data Item Primary Tumor Entity  
Breast Cancer Endometrial Cancer
Number of patients (N = 44) 28 16
Total number of procedures (N = 150) 82 68
Completed procedures 78 (95.1%) 62 (91.2%)
Completed PIPACs per patient 3 (1–4), range 0–9 3.5 (1–6.75), range 0–10
7–10 procedures 1 (3.6%) 4 (25.0%)
4–6 procedures 9 (32.1%) 4 (25.0%)
2 or 3 procedures 7 (25.0%) 3 (18.8%)
1 procedure 10 (35.7%) 2 (12.5%)
0 procedures 1 (3.6%) 3 (18.8%)
Primary non-access 1 (1.3%) 3 (4.8%)
Secondary non-access 1 (1.3%) 2 (3.2%)
RECIST
Complete remission 3 (10.7%)
Partial remission 9 (32.1%) 4 (25.0%)
Stable disease 3 (10.7%) 2 (12.5%)
Disease progression 1 (6.3%)
Not determined / too few PIPACs 13 (46.4%) 9 (56.3%)
Overall peri−/postoperative morbidity 1 (0–2), range 0–4 1 (0–2), range 0–4
Total number of adverse events 83 68
Procedures without complications 34 (40.9%) 28 (41.2%)
CTCAE grade 1 21 (25.3%) 21 (30.9%)
CTCAE grade 2 19 (22.9%) 16 (23.5%)
CTCAE grade 3 7 (8.4%) 3 (4.4%)
CTCAE grade 4 2 (2.4%)
Overall peri−/postoperative mortality 0 0
  1. Values are counts (percentage proportions; due to rounding, sums may not add up to 100%) or medians (interquartile ranges). Peri−/postoperative morbidity data give the median (interquartile range) and range of complications per procedure and the number (proportion) of procedures where the highest indicated CTCAE grade occurred. CTCAE Common Terminology Criteria for Adverse Events (Version 4.03), PIPAC Pressurized intraperitoneal aerosol chemotherapy, RECIST Response evaluation criteria in solid tumors